Amgen focuses on early intervention for ASCVD management

Amgen focuses on early intervention for ASCVD management
Amgen's ASCVD management

Amgen highlights the importance of early-stage intervention in managing atherosclerotic cardiovascular disease (ASCVD). For many patients, a cardiovascular event signals the commencement of chronic disease management, which involves ongoing medical costs beyond the initial incident.

Amgen suggests positioning cardiologists and primary care physicians earlier in the treatment process to potentially improve patient outcomes. This approach may help mitigate long-term healthcare expenses related to ASCVD.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.